Search

Your search keyword '"Deckert S"' showing total 306 results
Start Over Author "Deckert S"
306 results on '"Deckert S"'

7. Wie belastbar ist die Evidenz für positive Versorgungseffekte von DiGA? Ergebnisse eines Systematischen Reviews von DiGA-Zulassungsstudien

Author

Sippli, K, Deckert, S, Prinz, D, Donix, L, Schmitt, J, Horenkamp-Sonntag, D, Marschall, U, Schumacher, C, Saam, J, Janke, AL, Rumbler, A, Nussbaum, U, Wolter, A, Ferber, O, Buchinger, EM, Wittmann, D, Krieger, C, Kiessling, T, Henz, L, Mangiapane, N, Hassel, J, Scheibe, M, Sippli, K, Deckert, S, Prinz, D, Donix, L, Schmitt, J, Horenkamp-Sonntag, D, Marschall, U, Schumacher, C, Saam, J, Janke, AL, Rumbler, A, Nussbaum, U, Wolter, A, Ferber, O, Buchinger, EM, Wittmann, D, Krieger, C, Kiessling, T, Henz, L, Mangiapane, N, Hassel, J, and Scheibe, M

Published
2024

10. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).

Author

Chalmers, JR, Schmitt, J, Apfelbacher, C, Dohil, M, Eichenfield, LF, Simpson, EL, Singh, J, Spuls, P, Thomas, KS, Admani, S, Aoki, V, Ardeleanu, M, Barbarot, S, Berger, T, Bergman, JN, Block, J, Borok, N, Burton, T, Chamlin, SL, Deckert, S, DeKlotz, CC, Graff, LB, Hanifin, JM, Hebert, AA, Humphreys, R, Katoh, N, Kisa, RM, Margolis, DJ, Merhand, S, Minnillo, R, Mizutani, H, Nankervis, H, Ohya, Y, Rodgers, P, Schram, ME, Stalder, JF, Svensson, A, Takaoka, R, Teper, A, Tom, WL, von Kobyletzki, L, Weisshaar, E, Zelt, S, and Williams, HC

Subjects
Humans, Dermatitis, Atopic, Treatment Outcome, Long-Term Care, Quality of Life, Clinical Trials as Topic, Patient Outcome Assessment, Skin, Clinical Sciences, Oncology and Carcinogenesis, Dermatology & Venereal Diseases
Abstract

This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure.

Published
2014

12. Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanoma

Author

Diazzi, S, Baeri, A, Fassy, J, Lecacheur, M, Marin-Bejar, O, Girard, C, Lefevre, L, Lacoux, C, Irondelle, M, Mounier, C, Truchi, M, Couralet, M, Ohanna, M, Carminati, A, Berestjuk, I, Larbret, F, Gilot, D, Vassaux, G, Marine, J, Deckert, M, Mari, B, Tartare-Deckert, S, Diazzi S., Baeri A., Fassy J., Lecacheur M., Marin-Bejar O., Girard C. A., Lefevre L., Lacoux C., Irondelle M., Mounier C., Truchi M., Couralet M., Ohanna M., Carminati A., Berestjuk I., Larbret F., Gilot D., Vassaux G., Marine J. -C., Deckert M., Mari B., Tartare-Deckert S., Diazzi, S, Baeri, A, Fassy, J, Lecacheur, M, Marin-Bejar, O, Girard, C, Lefevre, L, Lacoux, C, Irondelle, M, Mounier, C, Truchi, M, Couralet, M, Ohanna, M, Carminati, A, Berestjuk, I, Larbret, F, Gilot, D, Vassaux, G, Marine, J, Deckert, M, Mari, B, Tartare-Deckert, S, Diazzi S., Baeri A., Fassy J., Lecacheur M., Marin-Bejar O., Girard C. A., Lefevre L., Lacoux C., Irondelle M., Mounier C., Truchi M., Couralet M., Ohanna M., Carminati A., Berestjuk I., Larbret F., Gilot D., Vassaux G., Marine J. -C., Deckert M., Mari B., and Tartare-Deckert S.

Abstract

Lineage dedifferentiation toward a mesenchymal-like state displaying myofibroblast and fibrotic features is a common mechanism of adaptive and acquired resistance to targeted therapy in melanoma. Here, we show that the anti-fibrotic drug nintedanib is active to normalize the fibrous ECM network, enhance the efficacy of MAPK-targeted therapy, and delay tumor relapse in a preclinical model of melanoma. Acquisition of this resistant phenotype and its reversion by nintedanib pointed to miR-143/-145 pro-fibrotic cluster as a driver of this mesenchymal-like phenotype. Upregulation of the miR-143/-145 cluster under BRAFi/MAPKi therapy was observed in melanoma cells in vitro and in vivo and was associated with an invasive/undifferentiated profile. The 2 mature miRNAs generated from this cluster, miR-143-3p and miR-145-5p, collaborated to mediate transition toward a drug-resistant undifferentiated mesenchymal-like state by targeting Fascin actin-bundling protein 1 (FSCN1), modulating the dynamic crosstalk between the actin cytoskeleton and the ECM through the regulation of focal adhesion dynamics and mechanotransduction pathways. Our study brings insights into a novel miRNA-mediated regulatory network that contributes to non-genetic adaptive drug resistance and provides proof of principle that preventing MAPKi-induced pro-fibrotic stromal response is a viable therapeutic opportunity for patients on targeted therapy.

Published
2022

20. Empfehlungen für ein evidenzgeleitetes Pandemiemanagement. Ergebnisse des NUM-Projekts egePan Unimed

Author

Schmitt, J, Harst, L, Weber, TO, Ihle, P, Walther, F, Panchyrz, I, Weltermann, B, Schmidt, M, Paris, S, Karschau, J, Karch, A, Lieb, K, Wiegand, HF, Weber-Carstens, S, Weiß, B, Spinner, C, Weidlich, S, Müller, B, Kuhn, S, Rohde, G, Hinz, O, Haier, J, Schäfers, J, Bajbouj, M, Wolff-Menzler, C, Combs, S, Meyer, B, Apfelbacher, C, Drewitz, KP, Deckert, S, Ciesek, S, Drosten, C, Mayer, M, Geraedts, M, Evers, J, von Wagner, M, Schmitt, J, Harst, L, Weber, TO, Ihle, P, Walther, F, Panchyrz, I, Weltermann, B, Schmidt, M, Paris, S, Karschau, J, Karch, A, Lieb, K, Wiegand, HF, Weber-Carstens, S, Weiß, B, Spinner, C, Weidlich, S, Müller, B, Kuhn, S, Rohde, G, Hinz, O, Haier, J, Schäfers, J, Bajbouj, M, Wolff-Menzler, C, Combs, S, Meyer, B, Apfelbacher, C, Drewitz, KP, Deckert, S, Ciesek, S, Drosten, C, Mayer, M, Geraedts, M, Evers, J, and von Wagner, M

Published
2022

24. Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN)

Author

Schmitt, J., Deckert, S., Alam, M., Apfelbacher, C., Barbaric, J., Bauer, A., Chalmers, J., Chosidow, O., Delamere, F., Doney, E., Eleftheriadou, V., Grainge, M., Johannsen, L., Kottner, J., Le Cleach, L., Mayer, A., Pinart, M., Prescott, L., Prinsen, C. A.C., Ratib, S., Schlager, J. G., Sharma, M., Thomas, K. S., Weberschock, T., Weller, K., Werner, R. N., Wild, T., Wilkes, S. R., and Williams, H. C.

Published
2016
Full Text
View/download PDF

26. Author Reply to Peer Reviews of Blockade of pro-fibrotic response mediated by the miR-143/-145 cluster prevents targeted therapy-induced phenotypic plasticity and resistance in melanoma

Author

Tartare-Deckert, S., primary, Mari, B., additional, Deckert, M., additional, Marine, J.-C., additional, Vassaux, G., additional, Larbret, F., additional, Berestjuk, I., additional, Carminati, A., additional, Couralet, M., additional, Truchi, M., additional, Mounier, C., additional, Irondelle, M., additional, Lacoux, C., additional, Lefevre, L., additional, Girard, C.A., additional, Marin-Bejar, O., additional, Lecacheur, M., additional, Fassy, J., additional, Baeri, A., additional, and Diazzi, S., additional

Published
2021
Full Text
View/download PDF

27. Blockade of pro-fibrotic response mediated by the miR-143/-145 cluster prevents targeted therapy-induced phenotypic plasticity and resistance in melanoma

Author

Diazzi, S., primary, Baeri, A., additional, Fassy, J., additional, Lecacheur, M., additional, Marin-Bejar, O., additional, Girard, C.A., additional, Lefevre, L., additional, Lacoux, C., additional, Irondelle, M., additional, Mounier, C., additional, Truchi, M., additional, Couralet, M., additional, Carminati, A., additional, Berestjuk, I., additional, Larbret, F., additional, Vassaux, G., additional, Marine, J.-C., additional, Deckert, M., additional, Mari, B., additional, and Tartare-Deckert, S., additional

Published
2021
Full Text
View/download PDF

36. Evaluation of a Digital Decision Aid for Knee Replacement Surgery: A Stepped-Wedge, Cluster-Randomized Trial.

Author

Lützner, J, Deckert, S, Beyer, F, Hahn, W, Malzahn, J, Sedlmayr, M, Günther, KP, Schmitt, J, and Lange, T

Abstract

Background: We studied whether an individualized digital decision aid can improve decision-making quality for or against knee arthroplasty. Methods: An app-based decision aid (EKIT tool) was developed and studied in a stepped-wedge, cluster-randomized trial. Consecutive patients with knee osteoarthritis who were candidates for knee replacement were included in 10 centers in Germany. All subjects were asked via app on a tablet about their symptoms, prior treatments, and preferences and goals for treatment. For the subjects in the intervention group, the EKIT tool was used in the doctor-patient discussion to visualize the individual disease burden and degree of fulfillment of the indication criteria, and structured information on knee arthroplasty was provided. In the control group, the discussion was conducted without the EKIT tool in accordance with the local standard in each participating center. The primary endpoint was the quality of the patient's decision on the basis of the discussion of indications, as measured with the Hip and Knee Quality Decision Instrument (HK-DQI). (Registration number: ClinicalTrials.gov:NCT04837053). Results: 1092 patients were included, and data from 1055 patients were analyzed (616 in the intervention group and 439 in the control group). Good decision quality, as rated by the HK-DQI, was achieved by 86.0% of patients in the intervention group and 67.4% of patients in the control group (relative risk, 1.24; 95 % confidence interval, [1.15; 1.33]). Conclusion: A digital decision aid significantly improved the quality of decision-making for or against knee replacement surgery. The widespread use of this instrument may have an even larger effect, as this trial was conducted mainly in hospitals with high case numbers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. International experiences in the development of guideline-based quality indicators – a qualitative study

Author

Nothacker, M, Bolster, M, Steudtner, M, Arnold, K, Deckert, S, Becker, M, Kopp, I, and Schmitt, J

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Introduction: Evidence-based clinical guidelines play an important role in health care and can be a valuable source for quality indicators (QI). However, the link between guidelines and QI is often neglected. International methodological standards for the development of guideline-based QI are lacking.[for full text, please go to the a.m. URL], 18. Deutscher Kongress für Versorgungsforschung (DKVF)

Published
2019
Full Text
View/download PDF

41. Entwicklung von Qualitätsindikatoren für eine psychiatrische Versorgung

Author

Rüffer, F, Neumann, A, von Peter, S, Ignatvey, Y, Arnold, K, Deckert, S, Soltmann, B, Pfennig, A, Heinze, M, and Schmitt, J

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund: Das Innovationsfonds-geförderte Projekt PsychCare untersucht die Wirksamkeit sektorenübergreifender Versorgungsmodelle in der Psychiatrie im Rahmen einer prospektiven multizentrischen Beobachtungsstudie, um Nutzen, Kosten und Effizienz von Modellvorhaben nach §64b SGB V aus[zum vollständigen Text gelangen Sie über die oben angegebene URL], 18. Deutscher Kongress für Versorgungsforschung (DKVF)

Published
2019
Full Text
View/download PDF

47. Surfing the insulin signaling web

Author

Van Obberghen, E., Baron, V., Delahaye, L., Emanuelli, B., Filippa, N., Giorgetti-Peraldi, S., Lebrun, P., Mothe-Satney, I., Peraldi, P., Rocchi, S., Sawka-Verhelle, D., Tartare-Deckert, S., and Giudicelli, J.

Published
2001

48. Erarbeitung von Qualitätsindikatoren innerhalb deutscher S3-Leitlinienprojekte – Barrieren und förderliche Faktoren aus der Sicht von Leitlinienautoren

Author

Arnold, K, Breuing, J, Becker, M, Nothacker, M, Schmitt, J, and Deckert, S

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund: S3-Leitlinien geben auf der besten verfügbaren Evidenz sowie formalem Expertenkonsens basierende Handlungsempfehlungen zu definierten Gesundheitsproblemen. Sie sind somit Instrumente der Qualitätsentwicklung im Gesundheitswesen. Auf S3-Leitlinienempfehlungen basierende Qualitätsindikatoren[zum vollständigen Text gelangen Sie über die oben angegebene URL], 17. Deutscher Kongress für Versorgungsforschung (DKVF)

Published
2018
Full Text
View/download PDF

49. Evidenz- und konsensbasierter Standard für die Entwicklung von leitlinienbasierten Qualitätsindikatoren

Author

Schmitt, J, Deckert, S, Arnold, K, Becker, M, Brombach, M, Breuing, J, Bolster, M, Neugebauer, EAM, Pieper, D, and Nothacker, M

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund und Ziel: Trotz der hohen Relevanz von S3-Leitlinien für die medizinische Versorgung in Deutschland spielen Qualitätsindikatoren (QI) im Kontext von S3-Leitlinien für eine Verbesserung und Überprüfung der Versorgungsqualität bisher nur in ausgewählten Bereichen[zum vollständigen Text gelangen Sie über die oben angegebene URL], 17. Deutscher Kongress für Versorgungsforschung (DKVF)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results